A pullback in the number of names falling from recent highs, as earnings season wanes. Of the few companies making the list, AMRI was stopping the development of a drug, sending shares lower. Also of interest, a story at Seeking Alpha called into the question the ability of the firm to pays its dvidend.
No comments:
Post a Comment